Disability Transplant Expense Provision

A Disability Transplant Expense Provision is a provision in a disability insurance policy that covers the cost of an organ transplant in the event that the insured becomes disabled and requires a transplant as part of their treatment. This provision is often included as an optional rider to a disability insurance policy and can provide valuable coverage for individuals who are at risk of developing conditions that may require an organ transplant.

Key features of a Disability Transplant Expense Provision may include:

  • Coverage for the cost of the transplant procedure, including hospitalization, surgery, and follow-up care.

  • Coverage for travel expenses associated with obtaining the transplant, such as transportation and lodging costs.

  • Coverage for pre- and post-transplant expenses, such as medication and rehabilitation.

  • Limits on the amount of coverage provided for each transplant, as well as limits on the total amount of coverage available under the rider.

  • Exclusions for certain pre-existing conditions or other health factors that may make an individual ineligible for coverage under the provision.

For example, suppose an individual purchases a disability insurance policy with a Transplant Expense Provision rider. If the individual becomes disabled and requires a kidney transplant, the policy would provide coverage for the cost of the transplant procedure, as well as any associated travel and medical expenses. The amount of coverage provided by the rider would be subject to the limits and exclusions outlined in the policy.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.